STI & Women’s Health
Correct Treatment Starts With the Right Organism
NAAT panels detect and differentiate multiple organisms from a single specimen in one run. Getting the organism right the first time matters, because bacterial, fungal and parasitic causes need different treatment.
Vaginitis Symptoms Overlap. The Treatments Don’t.
Bacterial vaginosis, a Candida infection and trichomoniasis can present with nearly identical symptoms, but they call for an antibiotic, an antifungal or an antiparasitic respectively. Consolidating these targets into one NAAT run lets decentralized and point-of-care settings resolve an STI or vaginitis panel in a single visit rather than a follow-up appointment.
One Panel, Three Organisms, Three Extraction Challenges
Bacterial · Bacterial Vaginosis
Lyse
→
Extract
→
Amplify
→
Detect
Routine lysis, but still needs verifying alongside its harder-to-lyse neighbors in the same pool.
Fungal · Candida Group
Lyse
→
Extract
→
Amplify
→
Detect
Chitin-walled fungal cells resist standard lysis conditions tuned for bacteria.
Parasitic · T. vaginalis
Lyse
→
Extract
→
Hybridize
→
Silver-Stain
A protozoan parasite lyses by an entirely different mechanism than a bacterium or fungus.
Where QC Creates Value
A pooled panel testing for three or more organisms from one specimen has to get every target right, including the ones that are hardest to detect. Neither an internal control nor a fixed-schedule external control, on its own, fully exercises the workflow a real urogenital or vaginal specimen goes through.
Extraction & Amplification
Verifies the upstream steps, lysis and extraction, where most errors actually occur, well before a result reaches the detection step a lab is watching.
Patient Sample Similarity
Intact organisms in a matrix of red blood cells and epithelial cells benchmark the full process the way a real specimen would.
Independent Verification
An unbiased check of the full test system, independent of whichever manufacturer built the assay being verified.
Run automatically with every patient sample, the internal control never travels through the workflow at all; it confirms only that the run finished. A synthetic control enters at amplification, skipping lysis and extraction entirely, so it never challenges the step most likely to fail differently for a bacterium, a fungus and a protozoan sharing the same vial. Only a full-process control, built from intact, inactivated organisms in a patient-like matrix, exercises lysis through detection for every target in the pool the way an actual specimen would. That verification has to hold for every organism at once; CLIA sets its own numbered requirement for the extraction phase — see Pooled Targets below.
Evidence
Not Every Organism Clears the Bar Equally
A prospective multicenter validation of a molecular bacterial vaginosis and vaginitis panel (clinician-collected samples) found sensitivity of 95.0% for bacterial vaginosis, 91.7% for the primary Candida group and 96.5% for Trichomonas vaginalis, each measured separately rather than as one pooled result. A minor but more treatment-resistant Candida subgroup, C. glabrata, came in noticeably lower, at 84.7%.
Standard
CLSI MM17
Multiplex assays don’t validate like single-target tests; CLSI MM17 recommends an error-based approach instead of traditional single-measurand validation.
This entry-point framework holds across every application in this cluster. See it laid out at the cluster level on the Infectious Disease Testing overview.
What CLIA Requires for a Pooled Panel
42 CFR 493.1256(d)(3) sets the baseline control requirements for nonwaived testing. Two clauses apply directly to a pooled molecular STI or vaginitis panel.
- Extraction phase (d)(3)(iv): “Each test system that has an extraction phase, include two control materials, including one that is capable of detecting errors in the extraction process.”
- Molecular amplification (d)(3)(v): “Each molecular amplification procedure, include two control materials and, if reaction inhibition is a significant source of false negative results, a control material capable of detecting the inhibition.”
- Same regulation, broader scope: (d)(3)(i) additionally requires two control materials of different concentrations each day patient specimens are assayed, and (8) requires them to be tested in the same manner as a patient specimen.
- Satisfied for one target isn’t satisfied for the panel: the text doesn’t carve out an exception for the harder targets in a pool. A control never challenged with those organisms hasn’t actually met the requirement for the panel as a whole.
- CAP Checklists: the Molecular Pathology and Molecular Microbiology checklists add further control requirements specific to molecular test systems.
- Confirm before publish: current CAP item numbers should be verified against the live checklist by Quality/Regulatory.
- Tuned vs. independent: a control made by the assay’s own manufacturer can be tuned to pass on that assay; a third-party control has every incentive to report the truth instead.
- Every target, not just the dominant one: confirming Chlamydia trachomatis is a different exercise than confirming Trichomonas vaginalis, and a credible control has to do both.
- A defensible answer at inspection: independent verification gives a CAP or CLIA surveyor a documented, traceable answer for how a lab checks its pooled molecular process end to end.
A Control for STI and Vaginitis Panels
Two Research Use Only formulations, each pooling every target for its panel into a single vial rather than requiring one control per organism.
Both are manufactured from intact, inactivated organisms in a matrix of red blood cells and epithelial cells, used the same way a patient specimen is used. The split is target set: one control pools the three STI targets, the other pools the bacterial, fungal and parasitic causes of vaginitis.
STI Panel · CT/NG/TV
Research Use Only
MDx-Chex® for CT/NG/TV
Pooled full-process control for Chlamydia trachomatis, Neisseria gonorrhoeae and Trichomonas vaginalis assays in a single formulation, platform-agnostic.
Vaginitis Panel · BV, Candida & TV
Research Use Only
MDx-Chex® for MVP
Full-process control for bacterial vaginosis, the Candida group and T. vaginalis, platform-agnostic.
Documentation
Regulation
Standard
Portfolio
Full Molecular QC Line
Browse every Streck molecular control across applications, not just blood culture.
Build Your Control Alongside Your Assay
Developing a new STI or vaginitis panel, or adding a target Streck doesn’t yet cover? Streck co-develops full-process controls validated specifically for your platform, working through feasibility, design lock and transfer to manufacturing alongside your own assay timeline rather than after it ships.
Built for Full-Process Reliability
Independently manufactured controls that verify performance from extraction through detection on leading STI and vaginitis testing platforms.
54+
years of scientific excellence
Zero
FDA recalls
70,000+
labs worldwide rely on
Streck products
ISO 13485
certified manufacturing
